The common occurrence and serious outcome of prostate cancer skeletal lesions has prompted the National Cancer Institute Prostate Cancer Progress Review Group to state that there is a need to study prostate cancer skeletal metastasis and a need of animal models to address this disease. Unfortunately, there is a dearth of research activity in this field. In the current proposal, we attack this problem by combining experts in prostate cancer research with bone metabolism experts in four interrelated projects supported by two cores. Our ultimate goal is to define the cellular and molecular mechanisms that lead to prostate cancer skeletal metastases. The central theme of our Program is that the bone microenvironment has unique properties that foster the development of prostate cancer metastasis. These properties include a combination of factors that cause prostate cancer cells to migrate and attach to bone and enhance their ability to thrive in the bone microenvironment. To develop this theme, we will perform the following interactive projects: Project 1 will explore the role of stromal-derived factor in the bone marrow and its receptor on the prostate cancer cells that favor the cells' ability to metastasize to bone. Project 2 will develop the theme that protease-activated receptor 1 is an important mediator of prostate cancer skeletal metastasis. Project 3 will examine the mechanisms through which bone morphogenetic proteins contribute to development of osteoblastic lesions. Project 4 will explore the role of parathyroid hormone-related protein on the development of osteoblastic lesions at the metastatic site. These projects will be tied together through use of several animal models including SCID-human and ossicle development in vivo. The animal model and animal-related services will be supported by the Animal Core (Core A) in an efficient and cost-effective manner. Bone evaluation, including histomorphometry, densitometry and radiographic imaging will be supported by a Bone Core (Core B).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA093900-04
Application #
7282340
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mohla, Suresh
Project Start
2004-06-05
Project End
2009-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
4
Fiscal Year
2007
Total Cost
$1,434,433
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Urology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Miller, Dannah R; Tzeng, Cherng-Chyi; Farmer, Trey et al. (2018) Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. Cancer Lett 436:96-108
Machioka, Kazuaki; Izumi, Kouji; Kadono, Yoshifumi et al. (2018) Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget 9:16185-16196
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
Axelrod, Haley D; Valkenburg, Kenneth C; Amend, Sarah R et al. (2018) AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Mol Cancer Res :
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266
Wu, Amy; Liao, David; Kirilin, Vlamimir et al. (2018) Cancer dormancy and criticality from a game theory perspective. Cancer Converg 2:1
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Lee, Eunsohl; Wang, Jingcheng; Jung, Younghun et al. (2018) Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer. J Cell Biochem 119:3697-3705

Showing the most recent 10 out of 228 publications